Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension
Grant Jones, Jocelyn A. Ricard, Matthew K. Nock
Frontiers in Psychiatry June 24, 2024 DOI: 10.3389/fpsyt.2024.1169686 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cross-sectional analysis Longitudinal Peer reviewed |
|---|---|
| Population | Respondents to the National Survey on Drug Use and Health (2005–2014) |
| Intervention | Psilocybin |
| Topics | Psilocybin |
| Keywords | Nsduh Race Drug epidemiology Psilocybin research Racial health disparities Hypertension studies Psychedelic medicine |
| Citations | 5 |
| Key findings | Psilocybin use was associated with reduced odds of past-year hypertension only among Non-Hispanic White individuals, not among other racial or ethnic groups. |
Abstract
Background: Hypertension is a major source of morbidity and mortality worldwide, particularly for racial and ethnic minorities who face higher rates of hypertension and worse health-related outcomes. Recent research has reported on protective associations between classic psychedelics and hypertension; however, there is a need to explore how race and ethnicity may moderate such associations.
Methods: We used data from the National Survey on Drug Use and Health (2005–2014) to assess whether race and ethnicity moderate the associations between classic psychedelic use – specifically psilocybin – and past year hypertension.
Results: Hispanic identity moderated the associations between psilocybin use and past year hypertension. Furthermore, individuals who used psilocybin and identified as Non-Hispanic White had reduced odds of hypertension (aOR: 0.83); however, these associations were not observed for any other racial or ethnic groups in our study for individuals who used psilocybin.
Conclusion: Overall, our results demonstrate that the associations between psychedelics and hypertension may vary by race and ethnicity. Longitudinal studies and clinical trials can further advance this research and determine whether such differences exist in causal contexts. Project registration https://osf.io/xsz2p/?view_only=0bf7b56749034c18abb2a3f8d3d4bc0b .
Comparable studies
Other cross-sectional and survey studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Individuals who had consumed psilocybin mushrooms and experienced a psychologically... | 2016 | Cross-sectional survey | n = 1,993 |
| The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms Internet survey respondents reporting challenging experiences with psilocybin | 2016 | Questionnaire development and validation | |
| Psychedelics and Mental Health: A Population Study Adult population in the United States | 2013 | Cross-sectional survey | n = 130,152 |
| Cessation and reduction in alcohol consumption and misuse after psychedelic use Individuals with prior alcohol use disorder who reported cessation or reduction in... | 2019 | Cross-sectional survey | n = 343 |
| Patterns of simultaneous polysubstance use in drug using university students Drug-using university students | 2006 | Cross-sectional survey | n = 149 |
Citations in the library
Cited by 5
- The Emergence of Psilocybin in Psychiatry and Neuroscience Pharmaceuticals April 9, 2025
- Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder PLoS One May 7, 2025
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit–Risk Considerations in Policy and Clinical Development Biomolecules July 3, 2026
- Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA SAIMSARA Journal June 15, 2026
- Exploring the potential psychological predictors associated with changes in depression, anxiety, and well-being following naturalistic psychedelic use. Journal of Psychiatric Research November 1, 2025
Cites 16
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Cessation and reduction in alcohol consumption and misuse after psychedelic use Journal of Psychopharmacology May 14, 2019
- Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature BMC Psychiatry July 31, 2018
and 11 more in the library